Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial – Nature Medicine   Commentary on Twitter The SAVE-MORE phase 3 study demonstrates the efficacy of anakinra, an IL-1α/β inhibitor, in patients with COVID-19 and high serum levels of soluble plasminogen activator receptor, according […]

The post RCT: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels. appeared first on Links Medicus.